BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 14674001)

  • 21. Comparative value of BNP and NT-proBNP in diagnosis of heart failure.
    Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F
    Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
    Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
    Bettencourt P; Azevedo A; Pimenta J; Friões F; Ferreira S; Ferreira A
    Circulation; 2004 Oct; 110(15):2168-74. PubMed ID: 15451800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
    Lindahl B; Lindbäck J; Jernberg T; Johnston N; Stridsberg M; Venge P; Wallentin L
    J Am Coll Cardiol; 2005 Feb; 45(4):533-41. PubMed ID: 15708700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis.
    Budweiser S; Luchner A; Jörres RA; Heinemann F; Hitzl AP; Schmidbauer K; Riegger G; Pfeifer M
    Respir Med; 2007 Sep; 101(9):2003-10. PubMed ID: 17532200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Change of N-terminal pro-brain natriuretic peptide and big endothelin in patients undergoing coronary artery bypass grafting].
    Lu YF; Qi HW; Tang CZ; Wu MY; Wang Y; Zhao FH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Nov; 19(11):667-70. PubMed ID: 17996134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NT-proBNP in monitoring treatment of patients with congestive heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide.
    Jarai R; Iordanova N; Jarai R; Raffetseder A; Woloszczuk W; Gyöngyösi M; Geyer G; Wojta J; Huber K
    Eur Heart J; 2005 Feb; 26(3):250-6. PubMed ID: 15618049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of exercise pulmonary arterial hypertension in scleroderma.
    Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N
    J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Sfetsios T; Koliakos G; Parcharidis G; Settas L
    Int J Cardiol; 2007 Sep; 121(1):135-7. PubMed ID: 17088004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.
    Sir JJ; Chung WY; Hwang SJ; Kang HJ; Cho YS; Koo BK; Chae IH; Choi DJ; Kim HS; Sohn DW; Kim CH; Oh BH; Park YB; Choi YS
    Int J Cardiol; 2008 Jun; 126(3):322-32. PubMed ID: 17544525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NT-proBNP is not elevated in patients with obstructive sleep apnoea.
    Hübner RH; El Mokhtari NE; Freitag S; Rausche T; Göder R; Tiroke A; Lins M; Simon R; Bewig B
    Respir Med; 2008 Jan; 102(1):134-42. PubMed ID: 17892929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension.
    Bernal V; Pascual I; Esquivias P; García-Gil A; Mateo JM; Lacambra I; Serrano MT; Simón MA
    Transplant Proc; 2009 Apr; 41(3):987-8. PubMed ID: 19376405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.
    Behnes M; Brueckmann M; Ahmad-Nejad P; Lang S; Wolpert C; Elmas E; Kaelsch T; Gruettner J; Weiss C; Borggrefe M; Neumaier M
    Int J Cardiol; 2009 Jun; 135(2):165-74. PubMed ID: 18603317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.